Regulation, counter-regulation, and immunotherapy of autoimmune responses to immunologically privileged retinal antigens

Immunologic Research

Volumn 27, Issue 2-3, 2003, Pages 149-159

  Caspi, Rachel R ^a,b  

^a NATIONAL EYE INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Autoimmune disease; T Cells; Th1 Th2; Tolerance; Uveitis

Indexed keywords

DNA VACCINE; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; INTERLEUKIN 10; INTERLEUKIN 4; MONOCLONAL ANTIBODY; RETINA ANTIGEN;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; NONHUMAN; ONTOGENY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL; UVEITIS; VACCINATION;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOTHERAPY; RETINA; SELF TOLERANCE; UVEITIS;

EID: 0043022039     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:27:2-3:149     Document Type: Review

References (42)

1. Nussenblatt RB, Whitcup SM, Palestine AG: Uveitis: Fundamentals and Clinical Practice, 2nd ed. St. Louis, MO, Mosby - Year Book, Inc., 1996, pp. 22-26.
2. Caspi RR: Experimental autoimmune uveoretinitis - rat and mouse; in Cohen IR, Miller A, (eds). Animal Models for Autoimmune Diseases: A Guidebook. Academic Press, San Diego. 1994; pp. 57-81.
3. Gery I, Mochizuki M, Nussenblatt RB: Retinal specific antigens and immunopathogenic processes they provoke. Prog Retinal Res 1986;5:75-109.
4. Streilein JW: Regional immunity and ocular immune privilege. Chem Immunol 1999;73:11-38.
5. Streilein JW: Immunologic privilege of the eye. Springer Semin Immunopathol 1999;21:95-111.
6. Helbig H, Gurley RC, Palestine AG, et al.: Dual effect of ciliary body cells on T lymphocyte proliferation. Eur J Immunol 1990;20:2457-2463.
7. Caspi RR, Roberge FG, Nussenblatt RB: Organ-resident, nonlymphoid cells suppress proliferation of autoimmune T-helper lymphocytes. Science 1987;237:1029-1032.
8. Xu H, Wawrousek EF, Redmond TM, et al.: Transgenic expression of an immunologically privileged retinal antigen extraocularly enhances self tolerance and abrogates susceptibility to autoimmune uveitis. Eur J Immunol 2000;30:272-278.
9. Egwuagu CE, Charukamnoetkanok P, Gery I: Thymic expression of autoantigens correlates with resistance to autoimmune disease. J Immunol 1997;159:3109-3112.
10. Derbinski J, Schulte A, Kyewski B, Klein L: Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2001;2:1032-1039.
11. Liou GI, Fei Y, Peachey NS, et al.: Early onset photoreceptor abnormalities induced by targeted disruption of the interphotoreceptor retinoid-binding protein gene. J Neurosci 1998;18:4511-4520.
12. Caspi RR, Avichezer D, Chan C-C, et al. Immunologically privileged expression of a sequestered ocular antigen results in tolerance. FASEB J 2002;16:A 1066.
13. Sun B, Rizzo LV, Sun SH, et al.: Genetic susceptibility to experimental autoimmune uveitis involves more than a predisposition to generate a T helper-1-like or a T helper-2-like response. J Immunol 1997;159:1004-1011.
14. Caspi RR, Silver PB, Chan CC, et al.: Genetic susceptibility to experimental autoimmune uveoretinitis in the rat is associated with an elevated Th1 response. J Immunol 1996;157:2668-2675.
15. Silver PB, Chan CC, Wiggert B, Caspi RR: The requirement for pertussis to induce EAU is strain-dependent: B10.RIII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment. Invest Ophthalmol Vis Sci 1999;40:2898-2905.
16. Forrester JV, McMenamin PG: Immunopathogenic mechanisms in intraocular inflammation. Chem Immunol 1999;73:159-185.
17. Prendergast RA, Iliff CE, Coskuncan NM, et al.: T cell traffic and the inflammatory response in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 1998;39:754-762.
18. Caspi RR, Chan CC, Fujino Y, et al.: Recruitment of antigen-nonspecific cells plays a pivotal role in the pathogenesis of a T cell-mediated organ-specific autoimmune disease, experimental autoimmune uveoretinitis. J Neuroimmunol 1993;47:177-188.
19. Su SB, Silver PB, Zhang M, et al.: Pertussis toxin inhibits induction of tissue-specific autoimmune disease by disrupting G protein-coupled signals. J Immunol 2001;167:250-256.
20. Caspi RR. Immune mechanisms in uveitis. Springer Semin Immunopathol 1999;21:113-124.
21. Xu H, Rizzo LV, Silver PB, Caspi RR: Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis. Cell Immunol 1997;178:69-78.
22. Rizzo LV, Xu H, Chan CC, et al.: IL-10 has a protective role in experimental autoimmune uveoretinitis. Int Immunol 1998;10:807-814.
23. Sun B, Sun SH, Chan CC, Caspi RR: Evaluation of in vivo cytokine expression in EAU-susceptible and resistant rats: a role for IL-10 in resistance? Exp Eye Res 2000;70:493-502.
24. Caspi RR, Chan CC, Grubbs BG, et al.: Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice. J Immunol 1994;152:890-899.
25. Chu CQ, Wittmer S, Dalton DK: Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J Exp Med 2000;192:123-128.
26. Caspi RR, Grubbs BG, Chan CC, et al.: Genetic control of susceptibility to experimental autoimmune uveoretinitis in the mouse model. Concomitant regulation by MHC and non-MHC genes. J Immunol 1992;148:2384-2389.
27. Hirose S, Ogasawara K, Natori T, et al.: Regulation of experimental autoimmune uveitis in rats - separation of MHC and non-MHC gene effects. Clin Exp Immunol 1991;86:419-425.
28. Sun SH, Silver PB, Caspi RR, et al.: Identification of genomic regions controlling experimental autoimmune uveoretinitis in rats. Int Immunol 1999;11:529-534.
29. Becker KG, Simon RM, Bailey-Wilson JE, et al.: Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci USA 1998;95:9979-9984.
30. Silver PB, Hathcock KS, Chan CC, et al.: Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol 2000;165:5041-5047.
31. Jones LS, Rizzo LV, Agarwal RK, et al.: IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol 1997;158:5997-6005.
32. Lafaille JJ, Keere FV, Hsu AL, et al.: Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med 1997;186:307-312.
33. Bielekova B, Goodwin B, Richert N, et al.: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000;6:1167-1175.
34. Kappos L, Comi G, Panitch H, et al.: Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000;6:1176-1182.
35. Nussenblatt RB, Caspi RR, Mahdi R, et al.: Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J Immunol 1990;144:1689-1695.
36. Rizzo LV, Miller-Rivero NE, Chan CC, et al.: Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity. J Clin Invest 1994;94:1668-1672.
37. Silver PB, Rizzo LV, Sun B, et al.: Heterologous epitopes of IRBP protect against autoimmune uveitis induced by the autologous epitope. J Neuroimmunol 1998;88:128-136.
38. Thurau SR, Chan CC, Nussenblatt RB, Caspi RR: Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals. Clin Exp Immunol 1997;109:370-376.
39. Nussenblatt RB, Gery I, Weiner HL, et al.: Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol 1997;123:583-592.
40. Rizzo LV, Morawetz RA, Miller-Rivero NE, et al.: IL-4 and IL-10 are both required for the induction of oral tolerance. J Immunol 1999;162:2613-2622.
41. Agarwal RK, Kang Y, Zambidis E, et al.: Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest 2000;106:245-252.
42. Agarwal R, Silver P, Su S-B, et al.: Vaccination with a plasmid encoding retinal interphotoreceptor retinoid-binding protein (IRBP) protects mice against experimental autoimmune uveitis (EAU). FASEB J 2002;16:A1066.